Enanta Pharmaceuticals to Participate in Investor Conferences in September
03 Settembre 2024 - 1:00PM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for virology and immunology indications, today announced that
members of management will participate in three investor
conferences being webcast in September:
- Baird 2024 Global Healthcare Conference: Fireside Chat at 2:35
p.m. ET on September 10, 2024
- H.C. Wainwright 26th Annual Global Investment Conference:
Fireside Chat at 10:00 a.m. ET on September 11, 2024
- 2024 Cantor Global Healthcare Conference: Fireside Chat at
10:55 a.m. ET on September 17, 2024
A live webcast of each event will be accessible by visiting the
“Events and Presentations” section on the “Investors” page of
Enanta’s website at www.enanta.com. A replay of the webcasts will
be available following the presentation and will be archived for at
least 30 days.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs with an emphasis on indications
in virology and immunology. Enanta’s research and development
programs are currently focused on respiratory syncytial virus (RSV)
and chronic spontaneous urticaria (CSU) and the company has
previously advanced clinical-stage compounds for SARS-CoV-2
(COVID-19) and chronic hepatitis B virus (HBV) infection.
Glecaprevir, a protease inhibitor discovered by Enanta, is part
of one of the leading treatment regimens for curing chronic
hepatitis c virus (HCV) infection and is sold by AbbVie in numerous
countries under the tradenames MAVYRET® (U.S.) and MAVIRET®
(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s
royalties from HCV products developed under its collaboration with
AbbVie contribute ongoing funding to Enanta’s operations. Please
visit www.enanta.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240903775265/en/
Media and Investors: Jennifer Viera 617-744-3848
jviera@enanta.com
Grafico Azioni Enanta Pharmaceuticals (NASDAQ:ENTA)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Enanta Pharmaceuticals (NASDAQ:ENTA)
Storico
Da Nov 2023 a Nov 2024